Related references
Note: Only part of the references are listed.Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer
Edward B. Garon et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Immunotherapy in the treatment of non-small cell lung cancer
Raghav Sundar et al.
LUNG CANCER (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
Eamon M. Berge et al.
SEMINARS IN ONCOLOGY (2014)
Hippocampus sparing in whole-brain radiotherapy
F. Oskan et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2014)
EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases
Dongdong Luo et al.
TUMOR BIOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Study finds different efficacy for afatinib in non-small-cell lung cancer cases with EGF receptor mutations
[Anonymous]
LUNG CANCER MANAGEMENT (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial
Xiao-xiao Dinglin et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases
Susan G. R. McDuff et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
Paul D. Brown et al.
NEURO-ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
Jens Koehler et al.
ONKOLOGIE (2013)
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial
Harriet B. Eldredge et al.
JOURNAL OF RADIATION ONCOLOGY (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
Mariam Jamal-Hanjani et al.
CLINICAL CANCER RESEARCH (2012)
Prognostic Indexes for Brain Metastases: Which Is the Most Powerful?
Gustavo Arruda Viani et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)
George R. Blumenschein
INVESTIGATIONAL NEW DRUGS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer
John D. O'Flaherty et al.
LUNG CANCER (2012)
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
F. Barlesi et al.
ANNALS OF ONCOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Time for Reappraisal of Extracranial Treatment Options? Synchronous Brain Metastases From Nonsmall Cell Lung Cancer
Joline S. W. Lind et al.
CANCER (2011)
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunotherapy for Non-small Cell Lung Cancer Novel Approaches to Improve Patient Outcome
Frances A. Shepherd et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer
Chang-Qi Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
Timothy C. Ryken et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
April F. Eichler et al.
NEURO-ONCOLOGY (2010)
Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer
Jennifer S. Temel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933
Vinai Gondi et al.
RADIOTHERAPY AND ONCOLOGY (2010)
The role of chemotherapy in the treatment of patients with brain metastases from solid tumors
Tobias Walbert et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular predictive and prognostic markers in non-small-cell lung cancer
Linda E. Coate et al.
LANCET ONCOLOGY (2009)
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
Eric L. Chang et al.
LANCET ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases
Dirk Rades et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2008)
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm
Elizabeth R. Gerstner et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
Hidefumi Aoyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Whole-brain radiotherapy in the management of brain metastasis
D Khuntia et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Current management of brain metastases, with a focus on systemic options
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiosurgery for treatment of brain metastases:: Estimation of patient eligibility using three stratification systems
J Lorenzoni et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Treatment of brain metastases from lung cancer: chemotherapy
W Schuette
LUNG CANCER (2004)
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial
CA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
The role of chemotherapy in brain metastases
MJ van den Bent
EUROPEAN JOURNAL OF CANCER (2003)
Radiosurgery for brain metastases: A score index for predicting prognosis
E Weltman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)